2[1]Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Ciin Cancer Res, 2001, 7(5): 1459
3[2]Perez-Soler R, Chachoua A, Huberman M, et al. A phase Ⅱ trail of the epidermal growth factor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing non-small cell lung cancer(NSCLC). Proc ASCO, 2001, 20:310A (Abstr 1235)
4[3]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol,2003, 21 (21) :2237
5[4]LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003, 9 (6) :2040
6[5]Giaccone G, Johnson DH, Manegold C, et al. A phase Ⅲ clinical trial of ZD 1839 (Iressa) in combination with gemcitibine and cisplatin in chemotherapy-naive patients with advanced non-smallcell lung cancer (INTACT1). Ann Oncol, 2002, 13:2
7[6]Johnson M, Herbst R, Giaccone G, et al. ZD1839 (Iressa)in combination with paclitaxel and carboplatin in chemotherapynaive patients with advanced non-small-cell lung cancer(NSCLC): Results from a phase Ⅲ clinical trail (INTACT2).Ann Oncol, 2002, 13:127
8[7]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004,350: 2129
9[8]Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497
10[9]Hidalgo M, Siu LL, Nemunaitis J, et al. Phase Ⅰ and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol, 2001, 19:3267
